Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:


Intestinal inflammation—key to complications in cirrhosis?

An ideal diagnostic test should be quick, reliable and noninvasive. Fecal calprotectin is considered a marker of intestinal inflammation and has proven to be an effective test for IBD, but is fecal calprotectin a useful diagnostic tool when assessing patients with cirrhosis?

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout


  1. Zwadlo, G., Schlegel, R. & Sorg, C. A monoclonal antibody to a subset of human monocytes found only in the peripheral blood and inflammatory tissues. J. Immunol. 137, 512–518 (1986).

    CAS  PubMed  Google Scholar 

  2. Gundling, F. et al. Fecal calprotectin is a useful screening parameter for hepatic encephalopathyand spontaneous bacterial peritonitis in cirrhosis. Liver Int. 31, 1406–1411 (2011).

    Article  CAS  PubMed  Google Scholar 

  3. Striz, I. & Trebichavsky, I. Calprotectin—a pleiotropic molecule in acute and chronic inflammation. Physiol. Res. 53, 245–253 (2004).

    CAS  PubMed  Google Scholar 

  4. Garcia-Sanchez, V. et al. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? J. Crohns Colitis 4, 144–152 (2010).

    Article  PubMed  Google Scholar 

  5. Homann, C. et al. Plasma calprotectin: a new prognostic marker of survival in alcohol-induced cirrhosis. Hepatology 21, 979–985 (1995).

    Article  CAS  PubMed  Google Scholar 

  6. Gupta, A. et al. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J. Hepatol. 53, 849–855 (2010).

    Article  PubMed  Google Scholar 

  7. Mullen, K. & Prakash, R. Rifaximin for the treatment of hepatic encephalopathy. Expert Rev. Gastroenterol. Hepatol. 4, 665–677 (2010).

    Article  CAS  PubMed  Google Scholar 

  8. Bajaj, J. S. et al. Review article: the design of clinical trials in hepatic encephalopathy—an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment. Pharmacol. Ther. 33, 739–747 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Prakash, R. K. & Mullen, K. D. Is poor quality of life always present with minimal hepatic encephalopathy? Liver Int. 31, 908–910 (2011).

    Article  PubMed  Google Scholar 

  10. Runyon, B. A. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 49, 2087–2107 (2009).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Ravi K. Prakash.

Ethics declarations

Competing interests

K. D. Mullen declares that he has worked as a consultant and been a member of a speakers bureau for Salix Pharmaceuticals. R. K. Prakash declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Prakash, R., Mullen, K. Intestinal inflammation—key to complications in cirrhosis?. Nat Rev Gastroenterol Hepatol 8, 665–667 (2011).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing